Clinical relevance of apoptotic markers in breast cancer not yet clear

被引:16
作者
Jager, JJ
Jansen, RLH
Arends, JW
机构
[1] Radiotherapeut Inst Limburg, NL-6401 CX Heerlen, Netherlands
[2] Univ Hosp Maastricht, Dept Internal Med, Maastricht, Netherlands
[3] Deventer Ziekenhuis, Dept Pathol, Deventer, Netherlands
关键词
apoptosis; apoptotic index; bcl-2; breast cancer; p53; prognosis;
D O I
10.1023/A:1016179530785
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Currently, the mainly used characteristics to predict outcome or treatment response in patients with breast cancer are tumor size, N-status, histological grade and receptor status (ER/PgR). However, these conventional clinico-pathological characteristics are of limited value. More accurate determinators are needed to select patients who are most likely to benefit from treatment in terms of prognosis as well as treatment response. Proliferation and apoptosis are assumed to play a key role in tumor progression as well as response to treatment. Currently, an increasing number of molecular factors controlling apoptosis as well as proliferation is known. The clinical relevance of apoptotic tumor markers in the treatment strategy of patients with breast cancer is the subject of this review. In addition, potential future developments are discussed.
引用
收藏
页码:361 / 365
页数:5
相关论文
共 58 条
[1]   Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome [J].
Aas, T ;
Geisler, S ;
Paulsen, T ;
BorresenDale, AL ;
Varhaug, JE ;
Lonning, PE ;
Akslen, LA .
ACTA ONCOLOGICA, 1996, 35 (05) :5-8
[2]   EXPRESSION OF RAS P21, P53 AND C-ERBB-2 IN ADVANCED BREAST-CANCER AND RESPONSE TO FIRST LINE HORMONAL-THERAPY [J].
ARCHER, SG ;
ELIOPOULOS, A ;
SPANDIDOS, D ;
BARNES, D ;
ELLIS, IO ;
BLAMEY, RW ;
NICHOLSON, RI ;
ROBERTSON, JFR .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1259-1266
[3]   p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer [J].
Berns, EMJJ ;
Klijn, JGM ;
van Putten, WLJ ;
de Witte, HH ;
Look, MP ;
Gelder, MEM ;
Willman, K ;
Portengen, H ;
Benraad, TJ ;
Foekens, JA .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :121-127
[4]  
Bottini A, 2000, CLIN CANCER RES, V6, P2751
[5]  
Brown JM, 1999, CANCER RES, V59, P1391
[6]  
Castiglione F, 1999, ANTICANCER RES, V19, P4555
[7]   p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer [J].
Clahsen, PC ;
van de Velde, CJH ;
Duval, C ;
Pallud, C ;
Mandard, AM ;
Delobelle-Deroide, A ;
van den Broek, L ;
Sahmoud, TM ;
van de Vijver, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :470-479
[8]   Primary chemotherapy in locally advanced breast cancer (LABC): Effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers [J].
Collecchi, P ;
Baldini, E ;
Giannessi, P ;
Naccarato, AG ;
Passoni, A ;
Gardin, G ;
Roncella, M ;
Evangelista, G ;
Bevilacqua, G ;
Conte, PF .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (11) :1701-1704
[9]   Clinical studies of Bcl-2 and treatment benefit in breast cancer patients [J].
Daidone, MG ;
Luisi, A ;
Veneroni, S ;
Benini, E ;
Silvestrini, R .
ENDOCRINE-RELATED CANCER, 1999, 6 (01) :61-68
[10]  
Daidone MG, 1999, INT J CANCER, V84, P580, DOI 10.1002/(SICI)1097-0215(19991222)84:6<580::AID-IJC7>3.0.CO